Drug Search Results
More Filters [+]

Dequalinium chloride

Alternative Names: dequalinium chloride, dequadin
Latest Update: 2023-09-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: Gram+ Bacteria Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Vaginal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Ireland | Italy | Lebanon | Malaysia | Mexico | New Zealand | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Medinova AG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dequalinium chloride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Vaginosis, Bacterial|Vaginal Diseases|Candidiasis, Vulvovaginal

Phase 3: Vaginosis, Bacterial|Vaginal Diseases|Pseudomonas Infections|Gram-Positive Bacterial Infections|Gram-Negative Bacterial Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MNFM380119

P4

Terminated

Vaginal Diseases|Vaginosis, Bacterial

2022-08-25

2020-002489-15

P4

Terminated

Vaginosis, Bacterial

2022-08-15

DEVA

P4

Unknown status

Vaginosis, Bacterial

2022-03-22

NCT04057482

N/A

Completed

Vaginosis, Bacterial|Vaginal Diseases

2017-12-01

Recent News Events